
Lindy Fishburne
Managing Partner
Co-founder and investor supporting science-driven founders, company strategy and board work.
United States / Direct investor

Backing companies built on science.
Early-stage venture investing in biology, chemistry and technology that turns scientific work into products.
Connect Now01 / The fund
Breakout Ventures focuses on science-driven companies using technology, biology and chemistry. Its portfolio includes biological research tools, medicines, industrial biotechnology, advanced materials, sensors and laboratory automation.
The firm announced the close of its $114 million Fund III on March 10, 2026 and said it was actively making seed investments. This is the size of one fund, not a claim about total assets under management.
Official fund overview ↗ · Fund III announcement ↗ · Fund on X ↗02 / Portfolio
All 29 companies currently listed in the fund's directory, including historical relationships. Inclusion does not mean every holding remains active or independent. Exit labels below come from Breakout; company-event sources explain later changes.

Uses machine learning and measurements from human tumors to study cancer biology and develop medicines.
Holding source ↗
Develops methods to mature eggs outside the body for fertility treatment; its current platform is preclinical.
Holding source ↗
Uses genomics and AI to develop treatments targeting the immune cells that drive autoimmune disease.
Holding source ↗
Measures large numbers of protein interactions to help researchers discover and develop medicines.
Holding source ↗
Develops small protein-like molecules that carry medicines to particular tissues, starting with the brain.
Holding source ↗
Automates chemical analysis to support drug research, starting with tools that identify molecules by mass. This focus is described by Breakout.
Holding source ↗
Images individual living cells over time to measure how immune cells interact and respond.
Holding source ↗
Ferments microalgae to make specialized fats and oils for nutrition, health and other products.
Holding source ↗
Historically developed medicines targeting causes of neurodegenerative disease. The public company later became Quince and then IRulya.
Holding source ↗Current IRulya logo shown.
Company name changes ↓
Grows mycelium, the root-like structure of fungi, to make food, textiles and other products.
Holding source ↗
Uses engineered enzymes to make RNA, molecules that carry and control genetic instructions, for research and medicines.
Holding source ↗
Uses small laboratory-grown models of brain cells to support neuroscience drug research, according to Breakout.
Holding source ↗
Engineers a patient's immune cells, known as B cells, to produce therapeutic proteins inside the body.
Holding source ↗
Builds small models of the human immune system from cells to test and discover medicines.
Holding source ↗
Uses computational genetics to identify combinations of medicines that may work better together.
Holding source ↗
Developed technology to stabilize and concentrate biologic medicines for easier delivery.
Holding source ↗ Acquisition confirmation ↗
Develops biologic medicines intended to target cancer recurrence and spread.
Holding source ↗
Uses engineered microbes and fermentation to make bio-based chemicals and polymers.
Holding source ↗
Develops investigational implantable sensors that read muscle signals to control robotic devices.
Holding source ↗
Computer vision captures laboratory work to help teams track experiments and improve workflows.
Holding source ↗
Combines animal scent detection, sensors and machine learning to identify chemical signatures.
Holding source ↗
Pairs real-world sensors with machine learning to model human physiology, behavior and surroundings.
Holding source ↗
A blood-testing instrument measures physical properties of immune cells to help clinicians assess sepsis risk.
Holding source ↗
Develops an implantable electrical stimulation device intended to treat chronic migraine.
Holding source ↗
Captures laboratory actions, surroundings and instrument results to make scientific work easier to understand and repeat.
Holding source ↗
Uses electricity-driven chemical reactions to turn captured carbon dioxide into chemicals, materials and fuels.
Holding source ↗
Water-harvesting systems capture moisture from air to produce drinking water for homes and industry.
Holding source ↗
Uses computational tools and laboratory testing to develop catalysts, materials that speed reactions, for ammonia and other industrial chemicals.
Holding source ↗
Combines biology and materials science to develop alternatives to conventional materials.
Holding source ↗03 / Team & connect

Managing Partner
Co-founder and investor supporting science-driven founders, company strategy and board work.

Managing Partner
Co-founder and early investor supporting financing, company building and commercialization.

Partner
Investor focused on evaluating science-driven companies and helping founders translate research into products.

Associate
Investment-team associate with a neuroscience background; interested in science, emerging technology and company formation.
Public work contacts checked November 17, 2026. No guessed email addresses or X handles are shown. Jerry's email comes from his public July joining post, also reshared by the firm; his current role comes from the fund's team page.
04 / Fund network

Operating Partner
Helps portfolio companies commercialize scientific products. Her biography explicitly says she remains an operator rather than becoming a full-time investor.
Technical and commercial specialists listed by the fund, separate from its full-time investment contacts.




Venture Partner
Drug-development and business-development expertise.

Venture Partner
Biotechnology and business-development expertise.
The current team page lists Nima Ronaghi among venture partners. The March 2026 Fund III release described a promotion to Partner; the current page determines his placement here. Finance, legal and platform staff are not presented as investment contacts.
The Fund III announcement names Cortes Capital, S-Cubed Capital, The Kraft Group, Pinegrove Venture Partners, an affiliate of LH Capital, JIMCO and Korea Omega Investment Corporation. These are named examples, not a complete limited-partner list.
Fund III limited-partner source ↗